 | Up a level |
Fiaschetti, G; Castelletti, D; Zoller, S; Schramm, A; Schroeder, C; Nagaishi, M; Stearns, D; Mittelbronn, M; Eggert, A; Westermann, F; Ohgaki, H; Shalaby, T; Pruschy, M; Arcaro, A; Grotzer, M A (2023). Correction: Bone morphogenetic protein-7 is a MYC target with prosurvival functions in childhood medulloblastoma. Oncogene, 42(2), p. 168. Nature Publishing Group 10.1038/s41388-022-02555-9
Kurch, L; Hasenclever, D; Kluge, R; Georgi, T; Tchavdarova, L; Golombeck, M; Sabri, O; Eggert, A; Brenner, W; Sykora, K W; Bengel, F M; Rossig, C; Körholz, D; Schäfers, M; Feuchtinger, T; Bartenstein, P; Ammann, Roland; Krause, T; Urban, C; Aigner, R; ... (2019). Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH-HD2002 trial. Pediatric blood & cancer, 66(3), e27539. Wiley-Liss 10.1002/pbc.27539
Fiaschetti, G; Castelletti, D; Zoller, S; Schramm, A; Schroeder, C; Nagaishi, M; Stearns, D; Mittelbronn, M; Eggert, A; Westermann, F; Ohgaki, H; Shalaby, T; Pruschy, M; Arcaro, A; Grotzer, M A (2011). Bone morphogenetic protein-7 is a MYC target with prosurvival functions in childhood medulloblastoma. Oncogene, 30(25), pp. 2823-35. Basingstoke, UK: Nature Publishing Group 10.1038/onc.2011.10
